Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Low-Dose Yellow Fever Vaccine in Adults in Africa
Kimathi D. et al, (2025), New England Journal of Medicine, 392, 788 - 797
Comparative performance of the InBios SCoV-2 DetectTM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations
Kutima B. et al, (2024), Wellcome Open Research, 9, 349 - 349
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M. et al, (2023), Wellcome open research, 8
The global burden of Chikungunya fever among children: A systematic literature review and meta-analysis
Nyamwaya DK. et al, (2022), PLOS Global Public Health, 2, e0000914 - e0000914
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
Ojal J. et al, (2022), Wellcome Open Research, 6, 127 - 127
Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort study.
Nyamwaya DK. et al, (2022), PLoS medicine, 19
Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya
Nyagwange J. et al, (2022), Wellcome Open Research, 7, 69 - 69
Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
Orangi S. et al, (2022)
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
Etyang AO. et al, (2022), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74, 288 - 293
Using cross-species vaccination approaches to counter emerging infectious diseases.
Warimwe GM. et al, (2021), Nature reviews. Immunology, 21, 815 - 822
COVID-19 transmission dynamics underlying epidemic waves in Kenya.
Brand SPC. et al, (2021), Science (New York, N.Y.), 374, 989 - 994
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.
Kagucia EW. et al, (2021), Open forum infectious diseases, 8
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.
Adetifa IMO. et al, (2021), Nature communications, 12
Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
Ojal J. et al, (2021), Wellcome Open Research, 6, 127 - 127
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891